Rheumatoid arthritis (RA) sufferers are at an increased risk of dying due to cardiovascular disease. A new five year study published in BioMed Central’s open access journal Arthritis Research & Therapy showed that the risk of cardiovascular disease for people with RA is due to disease-related inflammation as well as the risk factors which affect the general population. Treatment of arthritis with disease modifying antirheumatic drugs (DMARDs) also reduced the patient’s risk of heart disease.

Over 400 people with RA were followed from date of diagnosis for five years. Progression of their disease was measured using chemical markers of inflammation and physical appearance. Treatment regimes were monitored along with risk factors for heart disease, including weight, cholesterol levels, blood pressure, diabetes and smoking.

After five years, 97% of the patients had been treated with DMARDs, reducing both the chemical markers of inflammation and the physical appearance of their arthritis. Patients were also looking after themselves better - fewer patients were smokers and their BMI, and blood pressure, had reduced (due in part to treatment for high blood pressure).

Analysis of the patient data revealed that a new cardiovascular event such as heart disease, stroke or DVT could be predicted by intensity of their arthritis and by presence of diabetes, high blood pressure, and the level of triglycerides. Encouragingly treatment with DMARDs decreased the risk but COX-2 inhibitors appeared to predict a new event.

Dr Wållberg-Jonsson from University Hospital, Umeå, in Sweden said, “Inflammation associated with rheumatoid arthritis increases patients risk of heart disease and other cardiovascular events. However it is possible to reduce this risk in a two-pronged attack by treating both the inflammation and traditional risk factors for heart disease.”

###

Notes to Editors

1. Cardiovascular events in early rheumatoid arthritis (RA) are a result of inflammatory burden and traditional risk factors: a five year prospective study
Lena Innala, Bozena Möller, Lotta Ljung, Staffan Magnusson, Torgny Smedby, Anna Södergren, Marie-Louise Öhman, Solbritt Rantapää-Dahlqvist and Solveig Wållberg-Jonsson
Arthritis Research & Therapy, (in press)

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central’s open access policy.

Article citation and URL available on request at .(JavaScript must be enabled to view this email address) on the day of publication.

2. Arthritis Research & Therapy is an international, peer-reviewed online journal, publishing original research, reviews, commentaries and reports on cellular and molecular mechanisms of arthritis, musculoskeletal conditions and systemic autoimmune rheumatic diseases and translation of this knowledge into advances in clinical care.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.

###

Contact: Dr. Hilary Glover
.(JavaScript must be enabled to view this email address)
44-203-192-2370
BioMed Central